$XERS

Xeris Biopharma Holdings, Inc.

Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. Its commercial products are Recorlev for endogenous hypercortisolemia in adults with Cushing’s syndrome when surgery is not an option or has not been curative; Gvoke, a ready-to-use glucagon product for severe hypoglycemia in pediatric and adult patients with diabetes age two years and above; and Keveyis for Primary Periodic Paralysis. Xeris is headquartered in Chicago, Illinois. The company is developing XP-8121, a once-weekly subcutaneous levothyroxine candidate for hypothyroidism, and pursues partnerships to apply its XeriSol and XeriJect formulation technologies to other companies’ drugs and biologics. It makes money from commercializing its products and seeks to broaden its revenue stream through commercial licensing agreements. Third parties manufacture, package, store and distribute its products.

0
1
0
—
$773K
McCulloch Kevin
100%
See all $XERS insider activity →

XERS, CARL Stocks Hit All-Time Highs Today – Here’s What Analysts Are Saying

Xeris Biopharma (XERS) and Carlsmed (CARL) shares hit all-time highs after strong Q3 earnings. Barclays called XERS' Q3 'impressive,' raising its target to $18. XERS expects Recorlev sales to hit $1B earlier. BTIG raised CARL's target to $26, citing strong growth prospects. XERS shares up 3.8%, CARL up 22%.

XERS sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning XERS (Xeris Biopharma Holdings, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent XERS coverage spans financial news, earnings and market movers.

In the last 30 days, XERS insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($773K). The most active reporter was McCulloch Kevin, See Remarks, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving XERS

AlphAI scores every news story that mentions XERS with an AI model for sentiment and relevance, and aggregates insider trades from Xeris Biopharma Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $XERS

Score

Midday Fly By: Qualcomm gives tepid Q1 view, Kimberly-Clark reports mixed Q3

Qualcomm (QCOM) reported Q4 earnings slightly above expectations but gave a lower-than-expected Q1 outlook. Kimberly-Clark (KMB) reported mixed Q3 results. Arm (ARM) beat Q2 estimates and provided an upbeat Q3 outlook. Microsoft (MSFT) will not expand its agreement with Nscale. Wendy's (WEN) rejected a takeover proposal. Apple (AAPL) plans a $7B bond offering. Palo Alto Networks (PANW) is in talks to acquire Clutch Security.

Related tickers